Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Atorvastatin (20mg) + Ezetimibe (10mg) Tablet
Therapeutic Category
Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*15
Price
₹0/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Atorable EZ 20 Tablet contains Atorvastatin 20mg + Ezetimibe 10mg, a powerful dual-mechanism combination used for the management of high cholesterol and mixed dyslipidemia. It helps in significantly lowering LDL cholesterol levels and reducing overall cardiovascular risk.
Atorvastatin works by inhibiting cholesterol synthesis in the liver, while Ezetimibe reduces cholesterol absorption from the intestine. This complementary mechanism provides enhanced lipid-lowering efficacy compared to statin monotherapy.
This tablet is commonly prescribed for patients who do not achieve target lipid levels with statins alone, making it suitable for long-term cardiac risk management. Its once-daily oral dosing supports better patient compliance in chronic therapy.
For PCD pharma franchise partners, Atorable EZ 20 Tablet is a high-demand cardiac care product, offered at the best price for PCD pharma franchise. Strong prescriber confidence, rising lifestyle-related cholesterol cases, and consistent market demand make it a valuable addition to any cardiology or lipid-lowering product portfolio.
Common side effects may include headache, muscle pain, abdominal discomfort, nausea, and diarrhea. Rare but serious side effects can include liver enzyme elevation, muscle injury (myopathy or rhabdomyolysis), or allergic reactions. Patients should consult a doctor if unexplained muscle pain or weakness occurs.
Atorable EZ 20 Tablet is indicated for the treatment of hypercholesterolemia, mixed dyslipidemia, and elevated LDL cholesterol levels, particularly in patients at increased risk of cardiovascular diseases such as coronary artery disease and stroke.
This medicine should be taken as prescribed, usually once daily, with or without food. Regular monitoring of lipid levels and liver function is recommended during treatment. Caution is advised in patients with liver disease, excessive alcohol use, or those taking other cholesterol-lowering medications.
Store Atorable EZ 20 Tablet in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children and do not use after the expiry date mentioned on the pack.
Composition : Methylprednisolone (8mg)
Composition : Methylprednisolone (4mg)
Composition : Methylprednisolone (16mg)
Composition : Hydroxychloroquine (200mg) Tablet
Composition : Ciclosporin (50mg) Capsule
Composition : Azathioprine 50mg Tablet
Composition : Methylprednisolone (500mg)
Composition : Methylprednisolone (40mg)
Composition : Methylprednisolone (125mg)
Composition : Methylprednisolone (1000mg) Injection
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This lipid-lowering combination has strong demand in the cardiology and metabolic care segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on cholesterol management and cardiovascular risk reduction portfolios.
Medical distributors and agencies can benefit from consistent demand for management of high cholesterol (dyslipidemia), prevention of heart attack and stroke, and long-term cardiovascular risk control. Atorvastatin 20mg reduces cholesterol production in the liver Ezetimibe 10mg reduces cholesterol absorption from the intestine Together, they provide dual-action lipid control, strengthening a reliable cardiology and metabolic health product portfolio.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for this lipid-lowering combination tablet with promotional support, monopoly rights, quality packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and medical agencies benefit from stable chronic prescription demand, cardiologist preference, long-term therapy usage, strong repeat sales, reliable supply chain support, and good margins when partnering for this cardiovascular product.
Medical distributors, stockists, and wholesalers interested in this combination tablet can contact Cafoli LifeCare Pvt Ltd to discuss franchise opportunities, pricing, and distribution support.